Life Sciences Weekly Podcast – Episode 2
Recorded: May 10, 2025

This week on Life Sciences Weekly, host Matt Davison breaks down a whirlwind of developments shaping the biotech, pharma, and medtech landscape. Tune in for a market recap as volatility rocks the sector, with biotech stocks tumbling after Dr. Vinay Prasad is named the new head of the FDA’s Center for Biologics Evaluation and Research (CBER). Discover why Prasad’s evidence-driven, no-nonsense approach to drug approvals is sending shockwaves through the industry-and what it could mean for gene therapy and vaccine developers.

Get the latest on FDA approvals, including new clearances for AI-powered imaging, at-home cancer screening, and rare disease treatments. Matt covers the FDA’s evolving regulatory pathways, missed approval deadlines amid HHS restructuring, and a notable slowdown in enforcement actions.

In funding news, hear about major venture rounds, strategic investments, and academic-industry partnerships fueling the next wave of innovation-even as IPO windows remain tight. Plus, get a snapshot of Q1’s M&A and licensing trends across medtech and biopharma.

The episode’s Industry Spotlight examines the intersection of regulatory change and unprecedented U.S. investment, with Gilead, AstraZeneca, Novartis, AbbVie, and others pouring billions into domestic R&D and manufacturing. As the FDA tightens its standards and the political climate shifts, find out how life sciences leaders are doubling down on American infrastructure and innovation.

Don’t miss this comprehensive roundup of the week’s top stories, market moves, and the forces shaping the future of life sciences. Subscribe now for your essential industry briefing!

With your Life Sciences Industry Guide, Matt Davison